FemHealth Ventures
VC Fund
New York, United States
FemHealth Ventures is a VC fund in New York focused on Health Care and Biotechnology. FemHealth Ventures invests in groundbreaking innovators in women’s health, focusing on drugs, devices, diagnostics, and digital applications. We are (re)imagining women’s health to include conditions that affect only women, affect mostly women, or appear differently in women.
- Total investments:
- 14
- Last investment:
- Lead investor:
- 7%
- Fund size:
- $32M
- Last fund:
Last updated:
For AI agents: llms.txt
Industries FemHealth Ventures invests in
Stages FemHealth Ventures invests in
Countries FemHealth Ventures invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Maneesha Ghiya
|
|||
Investment Focus
Industry
- Health Care 10 (71%)
- Biotechnology 7 (50%)
- Medical 4 (29%)
- Medical Device 3 (21%)
- Health Diagnostics 3 (21%)
Stage
- Series A 7 (50%)
- Funding Round 2 (14%)
- Seed 1 (7%)
- Series B 1 (7%)
- Series D 1 (7%)
Country
- United States 11 (79%)
- Canada 1 (7%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Maneesha Ghiya
Managing Partner and Founder
|
Managing Partner and Founder | Total investments: 3 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Rejoni
|
Rejoni uses bio-materials to develop medical devices that improve the outcome of minimally invasive and gynecological surgical procedures. | $25M / Venture - Series Unknown / Jun 16, 2026 | |
GT Medical Technologies
|
GT Medical Technologies is a medical technology company focused on improving outcomes for patients with brain tumors through treatment solutions. It was established by to address unmet needs in neuro-oncology and advance the standard of care for patients with operable brain tumors. The company's flagship product, GammaTile®, is an FDA-cleared,bioabsorbable collagen implant embedded with radiation seeds that delivers targeted radiation therapy directly to the surgical cavity immediately following tumor removal. By providing localized treatment at the time of surgery, GammaTile is designed to target residual cancer cells while reducing radiation exposure to surrounding healthy brain tissue. This approach aims to help prevent tumor recurrence and improve patient outcomes. | $100M / Series E / Jun 09, 2026 | |
Reunion Neuroscience
|
Reunion Neuroscience is a clinical-stage pharmaceutical company developing therapeutic solutions for underserved mental health conditions. The Company’s lead asset, RE104, is a proprietary, novel serotonergic psychedelic compound being developed as a potential fast-acting and durable antidepressant for patients suffering from postpartum depressionand other mental health conditions. Reunion is also developing the RE200 series, which includes compounds with the potential for more selective serotonin receptor activity and reduced psychoactivity for application in more chronic treatment paradigms and indications. | $133M / Series A / Sep 16, 2025 | |
GT Medical Technologies
|
GT Medical Technologies, Inc. (GT), an Arizona-based medical device company, is focused on improving the lives of patients with brain tumors. GT has developed an innovative approach to treatment by combining a conformable collagen matrix with brachytherapy (radiation) seeds. The company's first product, GammaTile™ is protected by 10 US and 2Canadian issued patents, and 1 EPO patent. The product has the promise to revolutionize treatment for 176,000 patients/year in the US alone. To date, we have treated 120 patients with recurrent brain tumors in a clinical trial at Barrow Neurological Institute (BNI) and observed significant clinical improvement. | $53.3M / Series D / Jan 16, 2025 | |
Cercle
|
Cercle advances women's healthcare by unlocking access to insights. Cercle’s platform, the Cercle Biomedical Graph™, transforms healthcare data at scale into real-time, high-quality insights that women's healthcare providers use to run more efficient businesses and provide personalized care. | $6M / Seed / Sep 18, 2024 | |
Kanvas Biosciences
|
Kanvas Biosciences developed cutting-edge imaging technology for microbial detection, providing unmatched speed, breadth, and adaptability. Kanvas aims to transform microbial research and infectious disease diagnostics through innovative imaging technology of the next generation. | $12.5M / Series A / Jul 01, 2024 | |
AOA
|
AOA Dx is a biotechnology company with a team of entrepreneurs that brings innovative, impactful, and cost-effective medical technologies from research and development into the hands of providers and patients. The company is driven by a mission to bring to market the first accurate early-stage non-invasive ovarian cancer diagnostic test that willimprove clinical practice and help reduce patient mortality. | $17M / Oct 11, 2023 | |
|
AOA
|
AOA Dx is a biotechnology company with a team of entrepreneurs that brings innovative, impactful, and cost-effective medical technologies from research and development into the hands of providers and patients. The company is driven by a mission to bring to market the first accurate early-stage non-invasive ovarian cancer diagnostic test that willimprove clinical practice and help reduce patient mortality. | $17M / Series A / Oct 11, 2023 | |
|
Rejoni
|
Rejoni uses bio-materials to develop medical devices that improve the outcome of minimally invasive and gynecological surgical procedures. | $26.3M / Series B / Dec 07, 2022 | |
Fogarty Institute of Innovation
|
The mission of the Fogarty Institute for Innovation is to promote medical innovation by providing support to promising innovators and researchers as they transform their creative ideas into practical solutions to improve patient care. They offer mentorship and education at every step of the process, coordinating access to intellectual, physical,and financial resources to propel medical concepts from initiation to application. | $5M / Series A / Nov 02, 2021 | |
| See all 14 investments → | |||
Co-Investors
Adaptive Capital Partners
2 deals together
AMED Ventures
2 deals together
Ascension Ventures
2 deals together
Avestria Ventures
2 deals together
Band of Angels
2 deals together
Cancer Fund
2 deals together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does FemHealth Ventures invest in?
FemHealth Ventures invests primarily in Health Care, Biotechnology and Medical startups, most often at Series A and Funding Round stage. Most of the 14 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact FemHealth Ventures?
Public channels for FemHealth Ventures include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at FemHealth Ventures?
The team at FemHealth Ventures includes Maneesha Ghiya (Managing Partner and Founder). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
